FDA’s Office of Dietary Supplement Programs (ODSP) is inviting stakeholders to participate in a public meeting (in person and virtually) on Friday, March 27, from 9 am to 3 pm ET, to discuss the evolving landscape of dietary supplement ingredients and how recent scientific and technological advances are shaping the industry.

The in-person meeting will be held at:

Human Foods Program
U.S. Food and Drug Administration
Wiley Auditorium
5001 Campus Drive
College Park, MD 20740

FDA said the event will include presentations to provide background on the following topics:

• The scope of the phrase “dietary substance for use by man to supplement the diet by increasing the total dietary intake” as used in DSHEA;
• New methodologies to produce existing dietary ingredients; and
• Specific ingredient types, including proteins, enzymes, and microbials.

The meeting will include an opportunity for interested parties to provide oral comment for FDA’s consideration. The agency will review input received at the public meeting and submitted to www.regulations.gov (docket number FDA-2026-N-2047) to determine next steps. Comments must be submitted on or before April 27, 2026.

Background

The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines “dietary supplement,” in part, as a product that contains one or more dietary ingredients, including “a dietary substance for use by man to supplement the diet by increasing the total dietary intake” (Section 201(ff)(1)(E) of the FD&C Act).

ODSP is holding a public meeting to gather stakeholder input regarding the meaning of this provision.

Scientific and technological advancements have led to an increase in the development of novel ingredients. For example, new technologies and approaches are being applied to the science of dietary supplements, including precision fermentation, cell culture technology, and recombinant production, which have led to the development of bioactive compounds derived from foods, plants, and other sources.

Accordingly, FDA said it would be helpful to better understand how these scientific and technical advancements intersect with dietary ingredient production to inform its assessment.

Additionally, the discussion will explore questions related to determining the identity of notable supplement ingredients like proteins, enzymes, and microorganisms, which are not specifically listed in section 201(ff)(1) of the FD&C Act. ODSP is interested in learning about the different attributes that are important for assessing identity.

Submitting Comments

Comments on Exploring the Scope of Dietary Supplement Ingredients must be submitted on or before April 27, 2026. Submit electronic comments to www.regulations.gov to docket number FDA-2026-N-2047. Written comments should be sent to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. All written comments should identify the docket number FDA-2026-N-2047.